London, UK--(Marketwire - October 23, 2007) -

                          SkyePharma PLC

        Paxil CR(R) - Settlement between GSK and Mylan on Generic Launch

LONDON, UK - 23 October, 2007 -- SkyePharma PLC (LSE: SKP) announces that Mylan
Inc. (NYSE: MYL) and its subsidiary Mylan Pharmaceuticals Inc. have entered into
a patent license and settlement agreement with GlaxoSmithKline (LSE: GSK) 
("GSK") relating to Paroxetine Hydrochloride (HCl) Extended-release (ER) 
Tablets, the generic version of GSK's Paxil CR(R).  All litigation between Mylan 
and GSK relating to Paroxetine HCl ER Tablets has been dismissed.

Mylan has reported that, under the agreement with GSK and an associated supply
and distribution agreement, Mylan is provided patent licenses and the right to
market all three strengths of Paroxetine HCl ER Tablets, 12.5 mg, 25.0 mg and
37.5 mg, beginning no later than 1 October, 2008.  Mylan was the first company
to file an ANDA containing a paragraph IV certification covering the 12.5 mg and
25.0 mg strengths.  Upon receipt of final approval from the U.S. Food and Drug
Administration on 29 June, 2007, Mylan became eligible for a 180-day period of
marketing exclusivity for these two tablet strengths.

Paxil CRTM is an improved formulation of the anti-depressant Paxil(R) developed
by SkyePharma with GSK using SkyePharma's GeomatrixTM technology. Sales of Paxil
CRTM in the first half of 2007 were US$154 million.  The majority of these sales
were in the US on which SkyePharma earned a royalty of 4%.

                                   -- ends --

For further information please contact:

SkyePharma PLC

Frank Condella, Chief Executive Officer
Ken Cunningham, Chief Operating Officer                       +44 207 491 1777
Peter Grant, Finance Director

Financial Dynamics (London enquiries)
David Yates / Deborah Scott                                   +44 207 831 3113

Trout Group (US enquiries)
Christine Labaree / Seth Lewis                                +1 617 583 1308

About SkyePharma PLC

Using its proprietary drug delivery technologies, SkyePharma develops new
formulations of known molecules to provide a clinical advantage and life-cycle
extension. The Company has eleven approved products in the areas of oral,
inhalation and topical delivery.  The Group's products are marketed throughout
the world by leading pharmaceutical companies. For more information, visit

                      This information is provided by RNS
            The company news service from the London Stock Exchange